Novo's Victoza won't face Teva copies until 2023. Can semaglutide fill the gap by then?

Novo Nordisk has at least four more years to build up its newer diabetes drugs before they'll have to compete with Teva's knockoff versions of its own blockbuster GLP-1 Victoza. And it's hoping to get its oral semaglutide—the first GLP-1 pill—to market by year's end.